MAIA - AMEX

MAIA Biotechnology, Inc.

MAIA·AMEX

$1.49

+4.2%

HealthcareBiotechnology

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$90.59M

EPS-0.7000

P/E Ratio-2.13

Earnings Date08/10/2026

9.70M

Assets

-4%

3Y-19.0%

5Y+1200.0%

10Y+459.0%

7.33M

Total Liabilities

12%

3Y+109.0%

5Y+210.0%

10Y+1689.0%

2.38M

Total Equity

-35%

3Y-72.0%

5Y-247.0%

10Y+79.0%

MAIA Biotechnology, Inc. Funding & Solvency Profile

MAIA · AMEX

Current Assets

Cash & Cash Equivalents8.66B

Net Receivables0.00

Inventory0.00

Other Current Assets-8.65B

Total Current Assets10 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets2.80K

Total Non-Current Assets3 K

Total Assets

9.70M

Financial Health Analysis

Current Ratio

1.66x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Debt-to-Equity Ratio

3.08x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

4 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

100% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

MAIA Biotechnology, Inc. Balance Sheet

MAIA • AMEX

MAIA Biotechnology, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	8.7B	9.6M	7.2M	11M	10.6M	663.5K	1.7M
Cash & Short-Term Investments	8.7B	9.6M	7.2M	11M	10.6M	663.5K	1.7M
Net Receivables	0.0	77.3K	144.7K	302.8K	43.7K	0.0	0.0
Other Receivables	0.0	77.3K	144.7K	302.8K	43.7K	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	98.2K	83K	25K
Other Current Assets	-8.6B	473.8K	268.7K	554.3K	-43.7K	0.0	0.0
Total Current Assets	9.7M	10.2M	7.6M	11.8M	10.7M	746.5K	1.7M
NON-CURRENT ASSETS
Other Non-Current Assets	2.8K	2.8K	2.8K	214K	654.7K	0.0	0.0
Total Non-Current Assets	2.8K	2.8K	2.8K	214K	654.7K	0.0	0.0
Total Assets	9.7M	10.2M	7.6M	12M	11.3M	746.5K	1.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2M	1.5M	1.6M	1.2M	960.4K	161.9K	169.2K
Accounts Payable	2M	1.5M	1.6M	1.2M	960.4K	154.9K	169.2K
Other Payables	0.0	0.0	0.0	0.0	0.0	7K	0.0
Accrued Expenses	0.0	1.4M	1.7M	2.1M	689.6K	58.8K	178.3K
Short Term Debt	0.0	0.0	0.0	0.0	0.0	32K	25K
Other Current Liabilities	3.8M	941.1K	1.6M	0.0	496K	1.4M	2.1K
Total Current Liabilities	5.8M	3.8M	4.9M	3.3M	2.1M	1.7M	374.6K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	431.8K	9.2K
Other Non-Current Liabilities	1.5M	2.7M	2.2M	245.3K	0.0	237.3K	26K
Total Non-Current Liabilities	1.5M	2.7M	2.2M	245.3K	0.0	669.1K	35.2K
Total Liabilities	7.3M	6.5M	7.1M	3.5M	2.1M	2.4M	409.7K
SHAREHOLDERS' EQUITY
Common Stock	3.9K	2.6K	1.7K	1.1K	758.0	443.0	442.0
Additional Paid-In Capital	112.1M	90.9M	64.5M	52.7M	37.6M	12.6M	9.2M
Retained Earnings	-109.6M	-87.2M	-64M	-44.2M	-28.4M	-15.9M	-9.3M
Accumulated Other Comprehensive Income/Loss	-50.2K	-30.6K	-16.3K	-16K	0.0	0.0	-104.4K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	-2K	0.0
Total Stockholders' Equity	2.4M	3.6M	477.5K	8.5M	9.2M	-3.3M	-172.9K
Total Equity	2.4M	3.6M	477.5K	8.5M	9.2M	-1.6M	1.3M
Minority Interest	0.0	0.0	0.0	0.0	0.0	1.7M	1.5M
SUMMARY
Total Liabilities & Equity	9.7M	10.2M	7.6M	12M	11.3M	746.5K	1.7M
Total Debt	0.0	0.0	0.0	0.0	0.0	463.8K	34.2K
Net Debt	-8.7B	-9.6M	-7.2M	-11M	-10.6M	-199.7K	-1.7M
Shares Outstanding	37,032,307	37,032,307	37,032,307	37,032,307	37,032,307	37,032,307	37,032,307

SEC Filings

MAIA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 22, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 16, 2026	April 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 08, 2026	April 08, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 07, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 02, 2026	March 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 31, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 27, 2026	March 27, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 23, 2026	December 31, 2025	2025	View Filing

Showing 1 to 10 of 143 filings

Related Guides

Blog Categories

Continue your MAIA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.